This invention is a pharmaceutical composition comprising of lithium as an active ingredient, to decrease intracellular calcium ion concentrations, and a beta-secretase inhibitor as an active ingredient, to reduce beta-secretase activity； for the treatment and prevention of disease, including disease characterized by the abnormal cleavage of amyloid precursor protein.
